Sumera I. Ilyas

9.4k total citations · 7 hit papers
57 papers, 4.6k citations indexed

About

Sumera I. Ilyas is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Sumera I. Ilyas has authored 57 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Surgery, 20 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Sumera I. Ilyas's work include Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), MicroRNA in disease regulation (10 papers) and Gallbladder and Bile Duct Disorders (8 papers). Sumera I. Ilyas is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), MicroRNA in disease regulation (10 papers) and Gallbladder and Bile Duct Disorders (8 papers). Sumera I. Ilyas collaborates with scholars based in United States, United Kingdom and Chile. Sumera I. Ilyas's co-authors include Gregory J. Gores, Shahid A. Khan, Robin Kate Kelley, Christopher L. Hallemeier, Emilien Loeuillard, Alphonse E. Sirica, Paul J. Brindley, Melinda Bachini, Sopit Wongkham and Alex Loukas and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Sumera I. Ilyas

51 papers receiving 4.5k citations

Hit Papers

Cholangiocarcinoma — evolving concepts and therapeutic st... 2013 2026 2017 2021 2017 2013 2021 2022 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cholangiocarcinoma — evolving concepts and therapeutic strategies
    2017 1.1k citations Sumera I. Ilyas, Shahid A. Khan et al. Nature Reviews Clinical Oncology profile →
  2. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
    2013 947 citations Sumera I. Ilyas, Gregory J. Gores Gastroenterology profile →
  3. Cholangiocarcinoma
    2021 463 citations Paul J. Brindley, Melinda Bachini et al. Nature Reviews Disease Primers profile →
  4. Emerging immunotherapy for HCC: A guide for hepatologists
    2022 158 citations Sumera I. Ilyas et al. profile →
  5. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
    2022 152 citations Sumera I. Ilyas, Gonzalo Sapisochín et al. profile →
  6. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
    2023 147 citations Domenico Alvaro, Gregory J. Gores et al. Journal of Hepatology profile →
  7. Cholangiocarcinoma — novel biological insights and therapeutic strategies
    2023 94 citations Sumera I. Ilyas, Silvia Affò et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sumera I. Ilyas United States 26 3.3k 1.9k 1.3k 1.3k 1.1k 57 4.6k
Hidenori Ojima Japan 38 2.9k 0.9× 2.6k 1.4× 1.5k 1.2× 2.0k 1.6× 1.2k 1.1× 124 6.0k
Zhao‐Chong Zeng China 37 1.1k 0.3× 1.5k 0.8× 1.2k 0.9× 2.2k 1.7× 1.4k 1.3× 198 5.1k
Seiji Satoh Japan 32 1.3k 0.4× 917 0.5× 1.4k 1.1× 1.8k 1.4× 439 0.4× 76 4.2k
Fumio Shimamoto Japan 40 1.4k 0.4× 2.2k 1.2× 1.7k 1.3× 1.3k 1.0× 509 0.5× 196 4.6k
Hirofumi Akita Japan 28 1.1k 0.3× 1.5k 0.8× 710 0.5× 1.1k 0.8× 813 0.8× 184 3.2k
Shunichi Tsujitani Japan 41 2.2k 0.7× 2.0k 1.1× 3.2k 2.4× 1.5k 1.1× 602 0.6× 198 6.1k
Ryusei Matsuyama Japan 37 814 0.2× 1.8k 1.0× 1.2k 0.9× 1.1k 0.8× 869 0.8× 168 3.8k
Aiwu Ruth He United States 32 594 0.2× 2.2k 1.2× 698 0.5× 1.5k 1.2× 935 0.9× 187 4.5k
Masao Kameyama Japan 31 930 0.3× 1.3k 0.7× 1.1k 0.8× 1.3k 1.0× 384 0.4× 158 3.4k
Xiaobo Yang China 30 547 0.2× 1.0k 0.6× 727 0.6× 1.0k 0.8× 999 0.9× 100 2.6k

Countries citing papers authored by Sumera I. Ilyas

Since Specialization
Citations

This map shows the geographic impact of Sumera I. Ilyas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumera I. Ilyas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumera I. Ilyas more than expected).

Fields of papers citing papers by Sumera I. Ilyas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumera I. Ilyas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumera I. Ilyas. The network helps show where Sumera I. Ilyas may publish in the future.

Co-authorship network of co-authors of Sumera I. Ilyas

This figure shows the co-authorship network connecting the top 25 collaborators of Sumera I. Ilyas. A scholar is included among the top collaborators of Sumera I. Ilyas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumera I. Ilyas. Sumera I. Ilyas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mun, Dong‐Gi, J. A. TOMLINSON, Amro M. Abdelrahman, et al.. (2024). Integrated multiomics evaluation identifies novel molecular cholangiocarcinoma subtypes. HPB. 26. S606–S606.
2.
Nasser‐Ghodsi, Navine, John E. Eaton, Byron H. Smith, et al.. (2024). Transplantation Within 6 Months of Registration Does not Enhance Survival for Patients With Perihilar Cholangiocarcinoma. Annals of Surgery. 283(2). 308–315. 1 indexed citations
3.
Guicciardi, Maria Eugenia, Erik Jessen, Jingchun Yang, et al.. (2024). IL-17 signaling in primary sclerosing cholangitis patient-derived organoids. Hepatology Communications. 8(6). 7 indexed citations
4.
Yonkus, Jennifer A., Amro M. Abdelrahman, Caitlin B. Conboy, et al.. (2024). YAP ‐ TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS Open Bio. 14(11). 1873–1887. 1 indexed citations
5.
Parthasarathy, Gopanandan, Amy S. Mauer, Emilien Loeuillard, et al.. (2024). Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 9(3). 7 indexed citations
6.
Lu, Haiyan, Roger K. Moreira, Taofic Mounajjed, et al.. (2024). Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB. 26(7). 938–948. 3 indexed citations
7.
Li, Binbin, Jingchun Yang, Emilien Loeuillard, et al.. (2024). Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. Journal of Hepatology. 80(6). 892–903. 12 indexed citations
8.
Ilyas, Sumera I., Silvia Affò, Lipika Goyal, et al.. (2023). Cholangiocarcinoma — novel biological insights and therapeutic strategies. Nature Reviews Clinical Oncology. 20(7). 470–486. 94 indexed citations breakdown →
9.
Garza‐Ramos, Cynthia De la, Seyed Ali Montazeri, Kaitlyn R. Musto, et al.. (2023). Outcomes of Radiation Segmentectomy for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease versus Chronic Viral Hepatitis. Journal of Hepatocellular Carcinoma. Volume 10. 987–996. 2 indexed citations
10.
Alvaro, Domenico, Gregory J. Gores, Joël Walicki, et al.. (2023). EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. Journal of Hepatology. 79(1). 181–208. 147 indexed citations breakdown →
11.
Brindley, Paul J., Melinda Bachini, Sumera I. Ilyas, et al.. (2021). Cholangiocarcinoma. Nature Reviews Disease Primers. 7(1). 463 indexed citations breakdown →
12.
Gile, Jennifer, Fang‐Shu Ou, Amit Mahipal, et al.. (2021). FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology. 5(5). 1228–1240. 6 indexed citations
13.
Loeuillard, Emilien, Jingchun Yang, EeeLN H. Buckarma, et al.. (2020). Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. Journal of Clinical Investigation. 130(10). 5380–5396. 232 indexed citations
14.
Buckarma, EeeLN H., Nathan W. Werneburg, Caitlin B. Conboy, et al.. (2020). The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Molecular Cancer Research. 18(10). 1574–1588. 20 indexed citations
15.
Mertens, Joachim C., Sumera I. Ilyas, & Gregory J. Gores. (2017). Targeting cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(4). 1454–1460. 67 indexed citations
16.
Ilyas, Sumera I. & Gregory J. Gores. (2017). Emerging molecular therapeutic targets for cholangiocarcinoma. Journal of Hepatology. 67(3). 632–644. 141 indexed citations
17.
Ilyas, Sumera I. & Mitesh J. Borad. (2016). The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. Journal of Gastrointestinal Oncology. 7(5). 789–796. 27 indexed citations
18.
Ilyas, Sumera I. & Gregory J. Gores. (2013). Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterology. 145(6). 1215–1229. 947 indexed citations breakdown →
19.
Lomberk, Gwen, Angela Mathison, Adrienne Grzenda, et al.. (2012). Sequence-specific Recruitment of Heterochromatin Protein 1 via Interaction with Krüppel-like Factor 11, a Human Transcription Factor Involved in Tumor Suppression and Metabolic Diseases. Journal of Biological Chemistry. 287(16). 13026–13039. 45 indexed citations
20.
Ilyas, Sumera I., Cathrine J. DeMars, Andrea Comba, et al.. (2010). Combinatorial Chemoprevention Reveals a Novel Smoothened-Independent Role of GLI1 in Esophageal Carcinogenesis. Cancer Research. 70(17). 6787–6796. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hidenori Ojima Breakdown of academic impact, for papers by Zhao‐Chong Zeng Breakdown of academic impact, for papers by Seiji Satoh Breakdown of academic impact, for papers by Fumio Shimamoto Breakdown of academic impact, for papers by Hirofumi Akita Breakdown of academic impact, for papers by Shunichi Tsujitani Breakdown of academic impact, for papers by Ryusei Matsuyama Breakdown of academic impact, for papers by Aiwu Ruth He Breakdown of academic impact, for papers by Masao Kameyama Breakdown of academic impact, for papers by Xiaobo Yang
Rankless by CCL
2026